Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies
- PMID: 17041811
- PMCID: PMC11136202
- DOI: 10.1007/s00018-006-6242-0
Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies
Abstract
Huntington's disease (HD) is a neurodegenerative disorder that usually starts in middle age and is characterized by involuntary movements (chorea), personality changes and dementia, leading to death within 10-20 years. The defective gene in HD contains a trinucleotide CAG repeat expansion within its coding region that expresses a polyglutamine repeat in the protein huntingtin. Together with the characteristic formation of aggregates in HD, aberrant protein interactions and several post-translational modifications affect huntingtin during disease progression and lead to the dysfunction and death of selective neurons in the brains of patients. The exact molecular mechanisms by which mutant huntingtin induces cell death are not completely understood but may involve the gain of new toxic functions and the loss of the beneficial properties of huntingtin. This review focuses on the cellular functions in which huntingtin is involved and how a better understanding of pathogenic pathways can lead to new therapeutic approaches.
Similar articles
-
[Huntington's disease: intracellular signaling pathways and neuronal death].J Soc Biol. 2005;199(3):247-51. doi: 10.1051/jbio:2005026. J Soc Biol. 2005. PMID: 16471265 Review. French.
-
Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.J Neurosci. 2001 Nov 1;21(21):8473-81. doi: 10.1523/JNEUROSCI.21-21-08473.2001. J Neurosci. 2001. PMID: 11606636 Free PMC article.
-
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.Biochim Biophys Acta. 2012 Feb;1822(2):101-10. doi: 10.1016/j.bbadis.2011.10.016. Epub 2011 Nov 4. Biochim Biophys Acta. 2012. PMID: 22080977 Free PMC article. Review.
-
Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?Pathol Biol (Paris). 2004 Jul;52(6):338-42. doi: 10.1016/j.patbio.2003.06.004. Pathol Biol (Paris). 2004. PMID: 15261377 Review.
-
Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.Hum Mol Genet. 2006 Jun 15;15(12):2015-24. doi: 10.1093/hmg/ddl125. Epub 2006 May 10. Hum Mol Genet. 2006. PMID: 16687439
Cited by
-
Brain activation of SIRT1: role in neuropathology.Mol Neurobiol. 2013 Dec;48(3):681-9. doi: 10.1007/s12035-013-8459-x. Epub 2013 Apr 25. Mol Neurobiol. 2013. PMID: 23615921 Review.
-
Expression of expanded CAG transcripts triggers nucleolar stress in Huntington's disease.Cerebellum. 2013 Jun;12(3):310-2. doi: 10.1007/s12311-012-0447-6. Cerebellum. 2013. PMID: 23315009
-
Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.Cell Mol Life Sci. 2012 Dec;69(24):4107-20. doi: 10.1007/s00018-012-1025-2. Epub 2012 May 25. Cell Mol Life Sci. 2012. PMID: 22627493 Free PMC article. Review.
-
Multiple pathways contribute to the pathogenesis of Huntington disease.Mol Neurodegener. 2006 Dec 16;1:19. doi: 10.1186/1750-1326-1-19. Mol Neurodegener. 2006. PMID: 17173700 Free PMC article.
-
Huntington's Disease and Striatal Signaling.Front Neuroanat. 2011 Aug 23;5:55. doi: 10.3389/fnana.2011.00055. eCollection 2011. Front Neuroanat. 2011. PMID: 22007160 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
